HomeCompareAVCNF vs BTI

AVCNF vs BTI: Dividend Comparison 2026

AVCNF yields 1666.67% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVCNF wins by $1839785666.22M in total portfolio value
10 years
AVCNF
AVCNF
● Live price
1666.67%
Share price
$0.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1839785666.26M
Annual income
$1,645,561,548,268,653.00
Full AVCNF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — AVCNF vs BTI

📍 AVCNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVCNFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVCNF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVCNF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVCNF
Annual income on $10K today (after 15% tax)
$141,666.67/yr
After 10yr DRIP, annual income (after tax)
$1,398,727,316,028,355.00/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, AVCNF beats the other by $1,398,727,316,025,986.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVCNF + BTI for your $10,000?

AVCNF: 50%BTI: 50%
100% BTI50/50100% AVCNF
Portfolio after 10yr
$919892833.15M
Annual income
$822,780,774,135,719.90/yr
Blended yield
89.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

AVCNF
No analyst data
Altman Z
-4.8
Piotroski
3/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVCNF buys
0
BTI buys
0
No recent congressional trades found for AVCNF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVCNFBTI
Forward yield1666.67%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$1839785666.26M$37.7K
Annual income after 10y$1,645,561,548,268,653.00$2,786.64
Total dividends collected$1825787439.21M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: AVCNF vs BTI ($10,000, DRIP)

YearAVCNF PortfolioAVCNF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$177,367$166,666.67$11,299$598.92+$166.1KAVCNF
2$2,952,503$2,762,720.66$12,794$703.91+$2.94MAVCNF
3$46,139,686$42,980,507.73$14,518$829.07+$46.13MAVCNF
4$677,098,258$627,728,794.51$16,513$978.64+$677.08MAVCNF
5$9,333,745,461$8,609,250,324.41$18,827$1,157.84+$9333.73MAVCNF
6$120,900,966,251$110,913,858,608.07$21,518$1,373.12+$120900.94MAVCNF
7$1,472,054,345,780$1,342,690,311,890.92$24,657$1,632.46+$1472054.32MAVCNF
8$16,853,789,214,559$15,278,691,064,574.45$28,329$1,945.74+$16853789.19MAVCNF
9$181,517,867,281,133$163,484,312,821,554.84$32,637$2,325.33+$181517867.25MAVCNF
10$1,839,785,666,259,465$1,645,561,548,268,653.00$37,708$2,786.64+$1839785666.22MAVCNF

AVCNF vs BTI: Complete Analysis 2026

AVCNFStock

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Full AVCNF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this AVCNF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVCNF vs SCHDAVCNF vs JEPIAVCNF vs OAVCNF vs KOAVCNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.